PharVision Advisers’s NIO NIO Stock Holding History

PharVision Advisers’s Portfolio NIO Stock Details NIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,259	Closed	-$98K	–	104
2026 Q1	$98K	Sell	16,259 -94,285	-85%	-$476K	0.99%	49
2025 Q4	$564K	Buy	110,544 +90,212	+444%	+$557K	0.29%	22
2025 Q3	$155K	Buy	+20,332	New	+$110K	0.09%	566

Other funds holding NIO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AMH

Aspex Management (HK) Central, Hong Kong $8.89B AUM 39.91% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PharVision Advisers's NIO Position: Q2 2026 in Review

PharVision Advisers sold out of NIO (NIO) in Q2 2026, closing a stake of 16,259 shares — an estimated $98K sold.

PharVision Advisers first reported a position in NIO in Q3 2025 and held it in 3 quarters. The position peaked at $564K in Q4 2025. 422 funds tracked by Wall St. Rank hold NIO as of Q2 2026.

PharVision Advisers reported no remaining NIO position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 16,259 NIO shares in Q2 2026, an estimated $98K.
PharVision Advisers first reported a position in NIO in Q3 2025 and held it in 3 quarters.
PharVision Advisers's NIO position peaked at $564K in Q4 2025.
422 funds tracked by Wall St. Rank held NIO as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.